Marburg Virus in depth.

Overview

Marburg virus disease (MVD) is a rare but devastatingly lethal hemorrhagic fever caused by Marburg virus (MARV) and Ravn virus (RAVV) — two species of the genus Marburgvirus in the family Filoviridae, which also contains the Ebola viruses. First identified in 1967 during simultaneous outbreaks in Marburg and Frankfurt, Germany, and Belgrade, Yugoslavia, Marburg was the first known filovirus. Case fatality rates in historical outbreaks have ranged from 24% to 88%, making MVD one of the most lethal infectious diseases known to medicine. The Egyptian fruit bat (Rousettus aegyptiacus) is the natural reservoir; humans acquire infection through contact with infected bats or their excreta in caves or mines, and subsequently transmit the virus to others through direct contact with blood and body fluids.

Unlike Ebola, which has generated large West African outbreaks (2014–2016: 28,616 cases), Marburg outbreaks have historically been smaller — but the 2004–2005 Angola outbreak caused 252 cases with 227 deaths (90% CFR), the worst single Marburg outbreak on record. Recent outbreaks in Equatorial Guinea (2023, 16 deaths) and Tanzania (2023, 8 cases) highlight the ongoing threat. No approved vaccine or antiviral treatment currently exists; clinical trials are urgently underway.

History & Origin

The 1967 Marburg outbreak originated from African green monkeys imported from Uganda for polio vaccine production at the Behringwerke pharmaceutical plant in Marburg, Germany. 31 people were infected (25 laboratory workers, 6 secondary cases), with 7 deaths. The causative virus was isolated and named after the city. A second outbreak occurred in Zimbabwe and South Africa in 1975 (3 cases, 1 death), and sporadic cases followed in Kenya (1980, 1987). The 1998–2000 outbreak in Durba, DRC (154 cases, 128 deaths, 83% CFR) occurred among gold miners working in Goroumbwa Mine — the first indication that caves or mines harboring bats were the primary spillover interface.

The Angola 2004–2005 outbreak — 252 cases, 90% CFR — remains the deadliest in history. The WHO response included extensive case-finding and community engagement in Uige Province. Subsequent investigations confirmed that Rousettus aegyptiacus colonies in Python Cave, Uganda have been the source of multiple spillover events. Annual "bat cave" ecotourism at Python Cave has been linked to several imported cases in tourists returning to the USA, Netherlands, and other countries.

Transmission

• Zoonotic spillover (bats to humans): Direct or indirect contact with Egyptian fruit bats or their excreta (urine, feces, saliva) in bat-inhabited caves, mines, or forests. Specific high-risk exposures: entering Python Cave (Uganda), Kitum Cave (Kenya), Goroumbwa Mine (DRC).
• Human-to-human (blood/body fluid contact): Direct contact with blood, vomit, feces, urine, saliva, semen, sweat, or tears of an infected person — or with surfaces/materials contaminated by these fluids. Primary route of outbreak amplification.
• Healthcare settings: Needlestick injuries, unprotected patient care, inadequate PPE — responsible for multiple outbreak amplification events. Healthcare workers are at extremely high risk.
• Sexual transmission: Marburg virus has been detected in semen for up to 7 weeks after recovery. Sexual transmission from convalescent men has been documented (analogous to Ebola sexual transmission).
• Funeral practices: Traditional washing and preparation of bodies for burial has been a major transmission amplifier in African outbreaks.
• NOT transmitted through casual contact, air, food, or water.

Symptom Timeline

Incubation: 2–21 days (usually 5–10 days).

Diagnosis

• RT-PCR: Gold standard for confirming Marburg infection; can detect virus from day 3 of illness; requires BSL-4 laboratory for definitive work.
• Virus isolation: Culture in BSL-4 containment; confirms viability; used for research and reference.
• Antigen-detection ELISA: Detects Marburg antigen in blood; useful in outbreak settings; can be done at BSL-3.
• IgM/IgG serology: IgM appears after day 5–7; useful for later-stage diagnosis and serosurveys.
• Rapid antigen tests: Field-deployable RDTs for Marburg are in development/limited deployment; critical need for outbreak response.
• Sample collection must follow strict BSL-4 protocols with full PPE; samples are extremely dangerous to handle.
• Clinical diagnosis in outbreak context: unexplained hemorrhagic fever + exposure history (bat cave, contact with MVD patient, endemic area) should trigger immediate isolation and notification.

Treatment

No approved antiviral treatment for Marburg virus disease exists. Management is entirely supportive.

Supportive Care

• Fluid resuscitation: Aggressive replacement of fluids and electrolytes lost through vomiting, diarrhea, and hemorrhage — oral rehydration salts if patient can drink; IV crystalloids for severe illness.
• Electrolyte management: Hypokalemia and hyponatremia are common and must be corrected.
• Pain management: Analgesics for myalgia and headache (avoid NSAIDs/aspirin — increase bleeding risk).
• Blood products: Fresh frozen plasma, platelets, and packed red blood cells for active hemorrhage — limited evidence base but standard of care in severe MVD.
• Anti-emetics and anti-diarrheal agents: Control GI losses.
• Antimalarials/antibiotics: Empirically treat concurrent malaria (endemic co-infection) and secondary bacterial infections.

Investigational Treatments

• Remdesivir (GS-5734): Showed efficacy against Marburg in non-human primate models; compassionate use considered; Phase 2 trials ongoing for Marburg.
• Monoclonal antibodies (MR191-N): Neutralizing antibody demonstrated 100% protection in NHP models; Phase 1 completed; compassionate use potential.
• Favipiravir: Broad-spectrum antiviral with Marburg activity in vitro; not definitively proven in vivo against Marburg.
• Small interfering RNA (TKM-Marburg): Lipid nanoparticle-encapsulated siRNA; protective in NHP models; clinical development ongoing.

Vaccines in Development

• cAd3-MARV (Sabin Vaccine Institute / Oxford): Chimpanzee adenovirus-vectored vaccine; Phase 1 completed in the USA showing robust T-cell and antibody responses. Candidate for emergency use in outbreak response. WHO is evaluating for emergency use listing.
• VSV-MARV (IAVI/Merck): Live-attenuated vesicular stomatitis virus expressing Marburg GP; similar platform to VSV-EBOLA (rVSV-ZEBOV, Ervebo); Phase 1 showing promising results.
• mRNA vaccines (Moderna/NIH): Lipid nanoparticle mRNA encoding Marburg glycoprotein; Phase 1 trials launched 2023; rapid production capability.
• HPIV3/Marburg (NIAID): Human parainfluenza virus 3 vector; intranasal administration; Phase 1 pending.
• No vaccine is currently approved for routine use. Emergency deployment protocols being developed for outbreak responders.

Recent Outbreaks

• Equatorial Guinea, 2023: First-ever Marburg outbreak in West Africa; 16 confirmed deaths; declared ended April 2023. Source: exposure to bat-inhabited caves.
• Tanzania, 2023: 8 confirmed cases, 5 deaths (62.5% CFR); Kagera region; ended June 2023. First Marburg outbreak in Tanzania.
• Rwanda, 2024: Outbreak in September–October 2024; 66 confirmed cases, 15 deaths; significant nosocomial (hospital) transmission among healthcare workers. Declared ended November 2024. Ring vaccination with investigational vaccines deployed.
• Ghana, 2022: 3 confirmed cases, 2 deaths; imported from Ashanti Region mine workers.
• Angola, 2004–2005: 252 cases, 227 deaths — worst outbreak on record (90% CFR).

Infection Control & Response

• Isolation: Immediately isolate all confirmed/suspected cases in dedicated Ebola/Marburg treatment units with barrier nursing.
• PPE: Full PPE required for all patient contact: double gloves, face shield, respirator (N95 minimum), gown, boots, apron. Powered air-purifying respirators (PAPRs) for aerosol-generating procedures.
• Contact tracing: 21-day monitoring of all contacts (maximum incubation period); twice-daily temperature checks.
• Safe burial practices: WHO-recommended safe and dignified burial by trained teams; no traditional body washing.
• Health worker protection: The 2024 Rwanda outbreak demonstrated that hospital-based transmission is a major risk — infection prevention and control (IPC) is critical.
• Community engagement: Critical for contact tracing cooperation, reducing fear-driven hiding, and safe burial compliance.
• Avoid bat-cave exposure: Travelers should avoid entering caves or mines with bat colonies in sub-Saharan Africa. If unavoidable: wear N95 masks, goggles, gloves, and protective clothing.

Frequently Asked Questions

Sources & Citations